- Home
- ICCM vs CMMB Comparison
ICCM vs CMMB Comparison
Compare ICCM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- CMMB
- Stock Information
- Founded
- ICCM 2006
- CMMB 2004
- Country
- ICCM Israel
- CMMB Israel
- Employees
- ICCM N/A
- CMMB N/A
- Industry
- ICCM
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- CMMB Health Care
- Exchange
- ICCM Nasdaq
- CMMB Nasdaq
- Market Cap
- ICCM 29.3M
- CMMB 27.0M
- IPO Year
- ICCM N/A
- CMMB N/A
- Fundamental
- Price
- ICCM $0.55
- CMMB $1.74
- Analyst Decision
- ICCM Strong Buy
- CMMB Strong Buy
- Analyst Count
- ICCM 2
- CMMB 3
- Target Price
- ICCM $2.70
- CMMB $5.67
- AVG Volume (30 Days)
- ICCM 1.1M
- CMMB 99.6K
- Earning Date
- ICCM 11-18-2024
- CMMB 11-14-2024
- Dividend Yield
- ICCM N/A
- CMMB N/A
- EPS Growth
- ICCM N/A
- CMMB N/A
- EPS
- ICCM N/A
- CMMB N/A
- Revenue
- ICCM $3,336,000.00
- CMMB N/A
- Revenue This Year
- ICCM $18.61
- CMMB N/A
- Revenue Next Year
- ICCM $54.91
- CMMB N/A
- P/E Ratio
- ICCM N/A
- CMMB N/A
- Revenue Growth
- ICCM 3.60
- CMMB N/A
- 52 Week Low
- ICCM $0.48
- CMMB $0.42
- 52 Week High
- ICCM $1.57
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ICCM 38.10
- CMMB 61.83
- Support Level
- ICCM $0.54
- CMMB $1.44
- Resistance Level
- ICCM $0.85
- CMMB $1.56
- Average True Range (ATR)
- ICCM 0.10
- CMMB 0.13
- MACD
- ICCM -0.02
- CMMB 0.04
- Stochastic Oscillator
- ICCM 4.35
- CMMB 70.91
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.